Zeit für ein Browserupdate

IE6 not supported.

Keine sichere Verbindung.

no ssl-connection established.

zum Inhalt springen   zur Suche springen   zum Hauptmenü springen  


Kopfbereich

Logo

THIS INFORMATION IS FOR NON-US HEALTHCARE PROVIDERS ONLY

Hauptnavigation

  • Home
  • Navigation

  • AOP Orphan announces EU Marketing Authorization for BESREMi®
    (Ropeginterferon alfa-2b) for rare blood cancer (PV)     … read more here

  • PROUD-PV …  … Ropeginterferon α-2b (AOP2014) versus Hydroxyurea in Polycythemia Vera

  • 48 Study Centers in 13 Countries … … includes centers all across Europe: locate your study center

  • The Study Drugs … … find your information about the study drugs AOP2014 and Hydroxyurea

PROUD-PV …

… is a randomized, multicenter, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia vera.

Learn more about PROUD-PV …

The Study Centers …

… are located all across Europe.

Find more information about the study centers…

Study Drugs …

… we provide some basic information about the study drugs AOP2014 (Ropeginterferon α-2b ) and Hydroxyurea.

Find your information …

Fußzeilennavigation

Copyright

zur Startseite von AOP Orphan - Logo von AOP Orphan

© 2018 AOP Orphan Pharmaceuticals AG

Created by VERDINO

This website may contain information about experimental drugs and indications (off label), not approved by the concerned Regulatory Authority. Please, check the local SmPC for applicable current information. AOP2014 is not approved in any country of the world for any indication and its efficacy and safety have not been established yet. Presented materials are not intended to be a medical advice on how to treat patients. Solely individual physicians are responsible for treatment related decisions.